Currently, multimodality treatments are applied to patients with malignancies, including surgery, chemotherapy, radiotherapy, monoclonal antibodies, tyrosine kinase inhibitors, endocrine therapy, immunotherapy, and antibody-drug conjugates. The survival of patients with malignancies improves under these multimodal therapies. However, the "radical cure" of cancer is still very difficult, and recurrence, metastasis, and treatment failure often occur. Primary, adaptive, and acquired drug resistances are major causes of treatment failure, and there are several well-studied molecular mechanisms, including apoptosis suppression, altered drug metabolism, epigenetic changes, enhanced DNA repair, and amplification of oncogenic signaling. At present, novel drugs based on immunotherapy, mutation-targeted agents, and antibody-drug conjugates are under research, and there is an urgent need to discover and elucidate the mechanisms of therapeutic resistance based on these new drugs. Moreover, the research on mechanisms of drug resistance of malignant tumors will help to develop new treatment modalities and improve the survival rate of cancer patients.
This Research Topic aims to discuss molecular mechanisms of drug resistance, particularly based on targeted agents and immunotherapy, where the underlying molecular biology may provide insights for the treatment of malignancies, and we also hope to provide valuable references for the evaluation of treatment outcomes, such as survival rate, disease-free survival rate, locoregional control of cancer patients through targeted signaling, as well as reversal of resistance-related signaling, which may contribute to survival rate improvement. We welcome submissions covering but not limited to the following sub-topics:
1) Resistance to therapies based on targeted agents and immunotherapy
2) Research on drug resistance induced by gene mutation
3) Drug resistance-associated metabolism alterations in malignant tumors
4) Drug resistance-associated alterations in malignant tumor immune environment
5) Novel drug design to prevent and overcome resistance to targeted therapies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Currently, multimodality treatments are applied to patients with malignancies, including surgery, chemotherapy, radiotherapy, monoclonal antibodies, tyrosine kinase inhibitors, endocrine therapy, immunotherapy, and antibody-drug conjugates. The survival of patients with malignancies improves under these multimodal therapies. However, the "radical cure" of cancer is still very difficult, and recurrence, metastasis, and treatment failure often occur. Primary, adaptive, and acquired drug resistances are major causes of treatment failure, and there are several well-studied molecular mechanisms, including apoptosis suppression, altered drug metabolism, epigenetic changes, enhanced DNA repair, and amplification of oncogenic signaling. At present, novel drugs based on immunotherapy, mutation-targeted agents, and antibody-drug conjugates are under research, and there is an urgent need to discover and elucidate the mechanisms of therapeutic resistance based on these new drugs. Moreover, the research on mechanisms of drug resistance of malignant tumors will help to develop new treatment modalities and improve the survival rate of cancer patients.
This Research Topic aims to discuss molecular mechanisms of drug resistance, particularly based on targeted agents and immunotherapy, where the underlying molecular biology may provide insights for the treatment of malignancies, and we also hope to provide valuable references for the evaluation of treatment outcomes, such as survival rate, disease-free survival rate, locoregional control of cancer patients through targeted signaling, as well as reversal of resistance-related signaling, which may contribute to survival rate improvement. We welcome submissions covering but not limited to the following sub-topics:
1) Resistance to therapies based on targeted agents and immunotherapy
2) Research on drug resistance induced by gene mutation
3) Drug resistance-associated metabolism alterations in malignant tumors
4) Drug resistance-associated alterations in malignant tumor immune environment
5) Novel drug design to prevent and overcome resistance to targeted therapies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
